8 November 2019
FIND Collaborate with SpeeDx and QuantuMDx
The Foundation for Innovative New Diagnostics (FIND) are supporting a collaboration with SpeeDx and QuantuMDx to assess the feasibility of...
29 October 2019
TGA Clears ResistancePlus® MG FleXible for Sale in Australia
The Therapeutic Goods Administration (TGA) have cleared ResistancePlus® MG FleXible for the Cepheid GeneXpert® System, and it is now available...
6 September 2019
SpeeDx Receives CE-IVD Clearance for ResistancePlus® MG FleXible
ResistancePlus® MG FleXible for the Cepheid GeneXpert® System is now CE-IVD and available for sale in Europe. The test detects...
21 August 2019
Grant Awarded to University Collaboration with SpeeDx
The Australian Research Council (ARC) awarded almost $5 million to a collaboration with SpeeDx and over 20 other organisations, for...
8 August 2019
SpeeDx collaborate on test for premature birth risk
Researchers at The University of Western Australia and King Edward Memorial Hospital have teamed up with SpeeDx to commercialise a...
6 August 2019
SpeeDx Raise US $15 million Equity from Northpond Ventures
Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets....
